

Barcelona, Spain
24th February 2020

Almirall and Paratek enter into a License Agreement for Seysara[®] in China

- **Almirall has been commercializing sarecycline (acne) in the US since January 2019. The drug was approved by the FDA in October 2018, following the acquisition of the US medical dermatology portfolio from Allergan.**
- **Seysara[®] to become the first dermatology product of Almirall's strategic portfolio in China.**
- **Seysara[®] Phase 3 study expected to start in 2020.**
- **Submission to regulatory body in 2023.**

Almirall, S.A. (ALM) has today announced that Seysara[®] (sarecycline), an innovative first in class tetracycline-derived oral antibiotic for the treatment of inflammatory lesions of moderate to severe non-nodular acne vulgaris, is expected to be submitted to NMDA in 2023. Almirall has the commercialization rights for the medicine in the US, and will develop it for acne in China under a License Agreement from Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK).

Under the terms of the agreement entered into between Almirall and Paratek, Almirall will be responsible for development, registration and commercialization of the product in China in exchange for royalties calculated as a percentage of net sales once the product is launched onto the market.

Seysara[®] represents the first dermatology product for Almirall to entry and for building the company's strategic dermatology portfolio in China.

"At Almirall we are convinced that the launch of Seysara[®] in China will be a big step forward for many patients with acne in the country. Moderate to severe acne is a widespread issue in China, and Seysara[®] will bring a new and innovative solution to these patients", Peter Guenter, CEO, Almirall, added.

Seysara[®] is an oral tablet taken once daily with or without food. It has shown significant reduction of inflammatory lesions as early as three weeks after the start of treatment and is generally safe and well tolerated. Seysara[®] is an innovative treatment for patients with moderate to severe acne.

The Food and Drug Administration (FDA) approved Seysara[®] in October 2018. In order to prove the efficiency and safety of the medicine in China, Almirall will conduct a Phase III and PK study among Chinese population starting in 2020.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded almost 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were 811 million euros. Almirall has c. 1,800.

For more information see www.almirall.com

About Seysara®

Seysara® (sarecycline) is a once-daily, oral tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Seysara® has proven to be a safe and effective treatment in two 12-week multicenter, randomized, double-blind, placebo-controlled studies (Study 1 [NCT02320149] and Study 2 [NCT02322866]). Efficacy was assessed in a total of 2002 subjects 9 years of age and older.

Media contact:

LLYC

María Reales

mreales@llorenteycuenca.com

Phone: (+34) 93 217 22 17

Corporate Communications contact:

Almirall

Noel Ortiz

noel.ortiz@almirall.com

Phone: (+34) 93 291 30 00

Investors' relations contact:

Almirall

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone: (+34) 93 291 3087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication [click here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.